12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMG 145: Phase II data

The double-blind, international Phase II RUTHERFORD trial in 168 patients with heFH on a stable dose of statin therapy with or without ezetimibe showed that 350 and 420 mg doses of subcutaneous AMG 145 given every 4 weeks each met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (43% and 55% vs. a 1% increase,...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >